Abstract
Neurodegenerative disorders (NDs) such as Huntingtons disease, Alzheimers disease, Parkinson disease, amyotrophic lateral sclerosis, spinal muscular atrophy, Friedreichs ataxia, and others are multi-factorial illnesses, in which many pathways (still poorly understood) act serially and in parallel to give a determined pathologic phenotype. Thus, presently there are no effective cures for these diseases. Some phenotypic as well as mechanistic features, common to the most of NDs, can be linked to epigenetic defects, that can lead to alteration of acetylation homeostasis and impairment of the histone acetyltransferase (HAT): histone deacetylase (HDAC) balance. Here we survey most of the recent applications of HDAC inhibitors in the cited NDs, and we make the point of our (up to now) knowledge about the involvement of singular HDAC/SIRT isoform in NDs and other CNS pathologies.
Keywords: Epigenetics, HDAC inhibitors, neurodegenerative disorders, Huntington's disease, Alzheimer's disease, Parkinson disease, amyotrophic lateral sclerosis, spinal muscular atrophy, Friedreich's ataxia
Current Pharmaceutical Design
Title: Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise
Volume: 15 Issue: 34
Author(s): Antonello Mai, Dante Rotili, Sergio Valente and Aleksey G. Kazantsev
Affiliation:
Keywords: Epigenetics, HDAC inhibitors, neurodegenerative disorders, Huntington's disease, Alzheimer's disease, Parkinson disease, amyotrophic lateral sclerosis, spinal muscular atrophy, Friedreich's ataxia
Abstract: Neurodegenerative disorders (NDs) such as Huntingtons disease, Alzheimers disease, Parkinson disease, amyotrophic lateral sclerosis, spinal muscular atrophy, Friedreichs ataxia, and others are multi-factorial illnesses, in which many pathways (still poorly understood) act serially and in parallel to give a determined pathologic phenotype. Thus, presently there are no effective cures for these diseases. Some phenotypic as well as mechanistic features, common to the most of NDs, can be linked to epigenetic defects, that can lead to alteration of acetylation homeostasis and impairment of the histone acetyltransferase (HAT): histone deacetylase (HDAC) balance. Here we survey most of the recent applications of HDAC inhibitors in the cited NDs, and we make the point of our (up to now) knowledge about the involvement of singular HDAC/SIRT isoform in NDs and other CNS pathologies.
Export Options
About this article
Cite this article as:
Mai Antonello, Rotili Dante, Valente Sergio and Kazantsev G. Aleksey, Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise, Current Pharmaceutical Design 2009; 15 (34) . https://dx.doi.org/10.2174/138161209789649349
DOI https://dx.doi.org/10.2174/138161209789649349 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Natural Compounds Used as Therapies Targeting to Amyotrophic Lateral Sclerosis
Current Pharmaceutical Biotechnology Oxidative Stress and Neurodegenerative Diseases: A Neurotrophic Approach
Current Drug Targets Proteasome Inhibition: A Promising Strategy for Treating Cancer, but What About Neurotoxicity?
Current Medicinal Chemistry RAGE, Diabetes, and the Nervous System
Current Molecular Medicine The Glutamatergic Hypothesis for Down Syndrome: The Potential Use of N-Methyl-D-Aspartate Receptor Antagonists to Enhance Cognition and Decelerate Neurodegeneration
CNS & Neurological Disorders - Drug Targets Remodeling Chromatin and Stress Resistance in the Central Nervous System: Histone Deacetylase Inhibitors as Novel and Broadly Effective Neuroprotective Agents
Current Drug Targets - CNS & Neurological Disorders Current Therapeutic Molecules and Targets in Neurodegenerative Diseases Based on in silico Drug Design
Current Neuropharmacology Editorial (Thematic Issue: Myokines and Exercise Training: More Shadows than Lights)
Current Pharmaceutical Design MicroRNA Dysregulation in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Assessment of Glomerular and Tubular Function
Current Pediatric Reviews Biological and Pharmacological Effects of Gamma-oryzanol: An Updated Review of the Molecular Mechanisms
Current Pharmaceutical Design The Endocannabinoid System in Peripheral Lymphocytes as a Mirror of Neuroinflammatory Diseases
Current Pharmaceutical Design Exercise-Induced MicroRNA Regulation in the Mice Nervous System is Maintained After Activity Cessation
MicroRNA Crosstalk Between Calpain and Calcineurin in Excitotoxic Neurodegeneration; Therapeutic Targets for the Treatment of Excitotoxic Neurodegeneration
Current Medicinal Chemistry - Central Nervous System Agents Inflammation in Neurodegenerative Disorders: Friend or Foe?
Current Aging Science Neuropathological Correlates of Cerebral Multimorbidity
Current Alzheimer Research Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) A Friend in Need May Not be a Friend Indeed: Role of Microglia in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets The Neuroprotective Role of PEDF: Implication for the Therapy of Neurological Disorders
Current Molecular Medicine Meet the Editorial Board:
Technology Transfer and Entrepreneurship (Discontinued)